Cellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results and Corporate Performance
November 02, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces that...
New Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination with External Radiation
October 30, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces data...
Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma
October 24, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces the design of...
Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors
October 17, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the Japanese...
Cellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering
October 12, 2017 11:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) ("Cellectar" or the "Company"), an oncology-focused biotechnology company, today announces the closing of...
Cellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-Market
October 10, 2017 13:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “Company”), an oncology-focused biotechnology company, today announced that it entered...
Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates
October 10, 2017 07:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis. and CASTRES, France, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), together...
Cellectar Biosciences to Present at The MicroCap Conference
September 29, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the “company”), today announced that president and CEO Jim...
Cellectar Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR 131
September 27, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces that a patient...
Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates
September 21, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), and Onconova Therapeutics...